Literature DB >> 2921668

Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity.

P A Van de Wiel1, N Bloksma, C F Kuper, F M Hofhuis, J M Willers.   

Abstract

Mice with solid Meth A sarcoma in the skin received an intravenous or intralesional injection of graded doses of recombinant human tumour necrosis factor (rTNF). Local treatment caused red discolouration and necrosis of the central portion of the tumour within 24 h over a larger range of doses than intravenous treatment. Effects showed a limited dose dependence and no significant correlation with subsequent cures, which were far more frequent after local treatment. A dose of rTNF that induced about equal macroscopic necrosis by both routes caused much more pronounced microscopic effects after local administration. Effects included mitotic arrest, granulocyte margination, endothelial damage, hyperaemia, congestion, oedema, and tumour cell necrosis. rTNF did not affect the Meth A cells in vitro. Locally injected skins showed moderate vascular effects which were more marked in tumour-bearing mice, but skin necrosis was absent. Data show that quantitative histology rather than macroscopically visible necrosis correlates with cure rates. A broad interference of rTNF with tumour blood supply seems to be a major cause of the induced necrosis. Granulocytes may be involved in vascular damage. The different effects of rTNF on skin and tumour indicate that tumour vasculature has enhanced susceptibility to rTNF and probably lesser repair capacity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2921668     DOI: 10.1002/path.1711570109

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity.

Authors:  P A van de Wiel; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Synergistic antitumor effect of an angiogenesis inhibitor (TNP-470) and tumor necrosis factor in mice.

Authors:  Katsumi Amikura; Seiki Matsuno; Shinichi Egawa
Journal:  Surg Today       Date:  2006-12-25       Impact factor: 2.549

3.  Synergic action between tumor necrosis factor and endotoxins or poly(A.U) on cultured bovine endothelial cells.

Authors:  P A van de Wiel; R H Pieters; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.

Authors:  M G Rosenblum; L Cheung; K Mujoo; J L Murray
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

5.  Effect of tumour necrosis factor and lipid A on functional and structural vascular volume in solid murine tumours.

Authors:  P A van de Weil; G J Bouma; A van der Pijl; E S Weitenberg; A W Lam; N Bloksma
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

6.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.

Authors:  P T Nooijen; E R Manusama; A M Eggermont; L Schalkwijk; J Stavast; R L Marquet; R M de Waal; D J Ruiter
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

7.  Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies.

Authors:  Leander Huyghe; Alexander Van Parys; Anje Cauwels; Sandra Van Lint; Stijn De Munter; Jennyfer Bultinck; Lennart Zabeau; Jeroen Hostens; An Goethals; Nele Vanderroost; Annick Verhee; Gilles Uzé; Niko Kley; Frank Peelman; Bart Vandekerckhove; Peter Brouckaert; Jan Tavernier
Journal:  EMBO Mol Med       Date:  2020-01-08       Impact factor: 12.137

8.  Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model.

Authors:  G Rowlinson-Busza; A Maraveyas; A A Epenetos
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.